These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37851297)

  • 21. Comparative Effectiveness of Sotatercept and Approved Add-On Pulmonary Arterial Hypertension Therapies: A Systematic Review and Network Meta-Analysis.
    Pitre T; Desai K; Mah J; Zeraatkar D; Humbert M
    Ann Am Thorac Soc; 2024 Aug; 21(8):1194-1203. PubMed ID: 38820258
    [No Abstract]   [Full Text] [Related]  

  • 22. Sotatercept as a next-generation therapy for pulmonary arterial hypertension: insights from the STELLAR trial.
    Kopeć G
    Cardiovasc Res; 2023 Dec; 119(16):e155-e157. PubMed ID: 37584249
    [No Abstract]   [Full Text] [Related]  

  • 23. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman AB; Ghofrani HA; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; de Oliveira Pena J; Badesch DB
    Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36041750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
    Barnes H; Brown Z; Burns A; Williams T
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk.
    Estrada RA
    Ann Intern Med; 2023 Jun; 176(6):JC69. PubMed ID: 37276594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.
    Blette BS; Moutchia J; Al-Naamani N; Ventetuolo CE; Cheng C; Appleby D; Urbanowicz RJ; Fritz J; Mazurek JA; Li F; Kawut SM; Harhay MO
    Lancet Respir Med; 2023 Oct; 11(10):873-882. PubMed ID: 37230098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.
    Benza RL; Gomberg-Maitland M; Elliott CG; Farber HW; Foreman AJ; Frost AE; McGoon MD; Pasta DJ; Selej M; Burger CD; Frantz RP
    Chest; 2019 Aug; 156(2):323-337. PubMed ID: 30772387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.
    Joshi SR; Liu J; Bloom T; Karaca Atabay E; Kuo TH; Lee M; Belcheva E; Spaits M; Grenha R; Maguire MC; Frost JL; Wang K; Briscoe SD; Alexander MJ; Herrin BR; Castonguay R; Pearsall RS; Andre P; Yu PB; Kumar R; Li G
    Sci Rep; 2022 May; 12(1):7803. PubMed ID: 35551212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.
    Torbicki A; Bacchi M; Delcroix M; Farber HW; Ghofrani HA; Hennessy B; Jansa P; Mehta S; Perchenet L; Pulido T; Rosenberg D; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Wei LJ; Channick R; Benza R
    Circ Cardiovasc Qual Outcomes; 2019 May; 12(5):e005095. PubMed ID: 31109190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension.
    Sahay S; Villasmil Hernandez N; Wang F; Wooten M; Nguyen DT; Fauvel C; Benza R; Graviss EA
    Chest; 2024 Aug; 166(2):373-387. PubMed ID: 38447640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New risk model by right ventricle - pulmonary arterial coupling and inferior vena cava from echocardiography in patients with conventional low-intermediate risk pulmonary artery hypertension under targeted treatment.
    Yang L; Luo D; Huang T; Li X; Zhang C; Fei H
    Echocardiography; 2024 Jun; 41(6):e15850. PubMed ID: 38818775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
    Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Park DH; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Lange TJ; Rosenkranz S
    Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 34737226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation effect of COMPERA 2.0 risk assessment model on prognosis of Chinese patients with pulmonary arterial hypertension].
    Liang YR; Yang YC; Yang BL; Zeng QX; Liu BY; Zhao Q; Luo Q; Zhao ZH; Yang T; Liu ZH; Xiong CM
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(18):1410-1416. PubMed ID: 37150694
    [No Abstract]   [Full Text] [Related]  

  • 35. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.
    Boucly A; Weatherald J; Savale L; de Groote P; Cottin V; Prévot G; Chaouat A; Picard F; Horeau-Langlard D; Bourdin A; Jutant EM; Beurnier A; Jevnikar M; Jaïs X; Simonneau G; Montani D; Sitbon O; Humbert M
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34737227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics, Long-term Survival, and Risk Assessment of Pediatric Pulmonary Arterial Hypertension in China: Insights From a National Multicenter Prospective Registry.
    Qian Y; Quan R; Chen X; Gu Q; Xiong C; Han H; Zhang G; Chen Y; Yu Z; Tian H; Liu Y; Zhu X; Li S; Zhang C; He J
    Chest; 2023 Jun; 163(6):1531-1542. PubMed ID: 36470418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.
    Caputo A; Papa S; Manzi G; Laviola D; Recchioni T; Severino P; Lavalle C; Maestrini V; Mancone M; Badagliacca R; Vizza CD
    Curr Heart Fail Rep; 2023 Aug; 20(4):263-270. PubMed ID: 37486563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Humbert M; Farber HW; Ghofrani HA; Benza RL; Busse D; Meier C; Hoeper MM
    Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 30923187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease.
    Li X; Sun X; Huang Y; Wang Y; Yang X; Wang J; Zhang N; Gu L; Zhang M; Wang Q
    Clin Rheumatol; 2019 Dec; 38(12):3619-3626. PubMed ID: 31385084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.